Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-05-24
2011-05-24
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S561000
Reexamination Certificate
active
07947739
ABSTRACT:
Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
REFERENCES:
patent: 4171377 (1979-10-01), Green et al.
patent: 4258030 (1981-03-01), Sasaki et al.
patent: 4465662 (1984-08-01), Sato et al.
patent: 4483867 (1984-11-01), Svahn et al.
patent: 4711782 (1987-12-01), Okada
patent: 5229135 (1993-07-01), Phillipon et al.
patent: 5242337 (1993-09-01), Greenwood et al.
patent: 5271945 (1993-12-01), Yoshioka
patent: 5506264 (1996-04-01), Fujimara et al.
patent: 5575987 (1996-11-01), Kamei et al.
patent: 5622657 (1997-04-01), Takada et al.
patent: 5650174 (1997-07-01), Muhammad et al.
patent: 5723269 (1998-03-01), Akagi et al.
patent: 5747030 (1998-05-01), Kohnert et al.
patent: 5807583 (1998-09-01), Kristensen et al.
patent: 5858411 (1999-01-01), Nakagami et al.
patent: 5874463 (1999-02-01), Ancira
patent: 5897910 (1999-04-01), Rosenberg
patent: 6051253 (2000-04-01), Zettler
patent: 6066339 (2000-05-01), Stark et al.
patent: 6113943 (2000-09-01), Okada et al.
patent: 6120802 (2000-09-01), Breitenbach
patent: 6159502 (2000-12-01), Russell Jones
patent: 6197331 (2001-03-01), Lerner et al.
patent: 6300369 (2001-10-01), Ancira
patent: 6433215 (2002-08-01), Jung et al.
patent: 6548084 (2003-04-01), Leonard et al.
patent: 6551616 (2003-04-01), Notario et al.
patent: 7192608 (2007-03-01), Ochiai
patent: 7235530 (2007-06-01), Blair et al.
patent: 7351740 (2008-04-01), Zerangue
patent: 2002/0132855 (2002-09-01), Nelson et al.
patent: 2003/0190353 (2003-10-01), Oosterbaan et al.
patent: 2004/0006021 (2004-01-01), Rojkjaer et al.
patent: 2004/0096499 (2004-05-01), Vaya
patent: 2004/0258753 (2004-12-01), Demeesteer
patent: 2005/0025825 (2005-02-01), Heasley et al.
patent: 2005/0059742 (2005-03-01), Jabbour et al.
patent: 2005/0244495 (2005-11-01), Moore et al.
patent: 2005/0245614 (2005-11-01), Moore et al.
patent: 2005/0267014 (2005-12-01), Rojkaer et al.
patent: 2006/0003006 (2006-01-01), Remon
patent: 2006/0018933 (2006-01-01), Vaya et al.
patent: 2006/0018934 (2006-01-01), Vaya
patent: 2006/0127476 (2006-06-01), Heasley et al.
patent: 2006/0193914 (2006-08-01), Ashworth
patent: 2006/0287258 (2006-12-01), Jabbour et al.
patent: 2007/0020335 (2007-01-01), Chen et al.
patent: 2007/0027210 (2007-02-01), Zerangue et al.
patent: 2008/0193414 (2008-08-01), Proudfoot
patent: 2008/0280981 (2008-11-01), Moore et al.
patent: 2009/0017114 (2009-01-01), Moore et al.
patent: 2009/0048341 (2009-02-01), Moore et al.
patent: 2009/0209646 (2009-08-01), Moore et al.
patent: 2009/0214644 (2009-08-01), Heasley et al.
patent: 2009/0215898 (2009-08-01), Moore et al.
patent: 2010/0280117 (2010-11-01), Patrick et al.
patent: 2086565 (1994-07-01), None
patent: 0 998 916 (2000-05-01), None
patent: 0998916 (2000-05-01), None
patent: 0 923 934 (2003-08-01), None
patent: 0923934 (2003-08-01), None
patent: 1 586 315 (2005-10-01), None
patent: 2073019 (1981-10-01), None
patent: 57059847 (1982-04-01), None
patent: 4-243825 (1992-08-01), None
patent: 621994 (1994-08-01), None
patent: 06219942 (1994-08-01), None
patent: 07206660 (1995-08-01), None
patent: 9077726 (1997-03-01), None
patent: 09124878 (1997-05-01), None
patent: 09255542 (1997-09-01), None
patent: 10-017497 (1998-01-01), None
patent: 2000-159674 (2000-06-01), None
patent: 2001-163774 (2001-06-01), None
patent: 2002-265358 (2002-09-01), None
patent: 9415904 (1994-07-01), None
patent: WO96/19200 (1996-06-01), None
patent: 2004028503 (2004-04-01), None
patent: WO 2004/028503 (2004-04-01), None
patent: WO2004/060364 (2004-07-01), None
patent: WO2005/011650 (2005-02-01), None
patent: WO2006/023000 (2006-03-01), None
patent: WO2006/023001 (2006-03-01), None
patent: 2008111096 (2008-09-01), None
patent: 2008148798 (2008-12-01), None
Wellington et al ‘Tranexamic Acid, A Review of its Use in the Management of Menorrhagia’ Drugs, 63(13), p. 1417-1433, 2003.
Bravo et al ‘In-Vitro Studies of Diclofenac Sodium Controlled-release from Biopolymeric Hydrophilic Matrices’ Journal of Pharmacy and Pharmaceutical Science, 5(3), p. 213-219, 2002.
Florence et al ‘Novel Oral Drug Formulation, Their Potential in Modulating Adverse Effects’ Drug Safety, 10(3), p. 233-266, 1994.
Cyklokapron® Package Insert, Pharmacia & Upjohn. Revised Oct. 2000, 6 pgs.
Cyklokapron® Package Insert, Pharmacia Canada, Inc., Misissauga, Ontario, (Nov. 2002).
Lee et al., “Treatment of Menorrhagia with Tranxamic Acid”,Fertility and Sterility, Oct. 18, 1997, Supple. 1, p. 96.
Shin-Yakuzaigaku Souron (New General Pharmaceutics), Nankodo, revised edition vol. 3, Apr. 10, 1987, pp. 287-291 (Note: An English translation of Table 10.2 is included), 6 pgs.
Stirrat, Gordon M., “Choice of treatment for menorrhagia”,The Lancet, Jun. 26, 1999, vol. 353, pp. 2175-2176.
Notice of Rejection dated Sep. 29, 2009 for Japanese Appln. No. 2006-521917 (with English translation), 25 pgs.
Final Rejection dated Oct. 12, 2010 for Japanese Appln No. 2006-521917 (with English translation), 6 pgs.
Notice of Rejection dated Sep. 3, 2010 for Japanese Appln. No. 2007-523555 (with English translation), 11 pgs.
Notice of Rejection dated Aug. 17, 2010 for Japanese Appln. No. 2007-523556 (with English translation), 11 pgs.
Office Action (Restriction Requirement) dated Feb. 14, 2008 for U.S. Appl. No. 11/072,194, 7 pgs.
Office Action (Restriction Requirement) dated Jul. 20, 2010 for U.S. Appl. No. 12/228,489, 5 pgs.
Office Action (Non-Final) dated Nov. 8, 2010 for U.S. Appl. No. 12/228,489, 16 pgs.
Office Action (Restriction Requirement) dated Nov. 27, 2007 for U.S. Appl. No. 11/072,162, 9 pgs.
Office Action (Non-Final) dated Jan. 23, 2008 for U.S. Appl. No. 11/072,162, 6 pgs.
Office Action (Final Rejection) dated Sep. 9, 2010 for U.S. Appl. No. 12/220,241, 8 pgs.
Office Action (Non-Final) dated Feb. 5, 2010 for U.S. Appl. No. 12/220,241, 7 pgs.
Office Action (Restriction Requirement) dated Oct. 20, 2009 for U.S. Appl. No. 12/220,241, 9 pgs.
Office Action (Examiner Interview Summary Record) dated Oct. 28, 2008 for U.S. Appl. No. 10/631,371, 2 pgs.
Office Action (Non-Final) dated Mar. 13, 2008 for U.S. Appl. No. 10/631,371, 7 pgs.
Advisory Action dated Oct. 23, 2007 for U.S. Appl. No. 10/631,371, 3 pgs.
Office Action (Final Rejection) dated Jun. 14, 2007 for U.S. Appl. No. 10/631,371, 9 pgs.
Office Action (Non-Final) dated Dec. 15, 2006 for U.S. Appl. No. 10/631,371, 6 pgs.
Office Action (Restriction Requirement) dated Aug. 25, 2006 for U.S. Appl. No. 10/631,371, 6 pgs.
Office Action (Restriction Requirement) dated Feb. 17, 2010 for U.S. Appl. No. 12/433,408, 8 pgs.
Office Action (Non-Final) dated Jul. 30, 2010 for U.S. Appl. No. 12/433,408, 7 pgs.
Office Action (Final Rejection) dated Dec. 6, 2010 for U.S. Appl. No. 11/346,710, 12 pgs.
Office Action (Non-Final) dated Mar. 18, 2010 for U.S. Appl. No. 11/346,710, 9 pgs.
Office Action (Restriction Requirement) dated Aug. 17, 2009 for U.S. Appl. No. 11/346,710, 7 pgs.
Office Action (Non-Final) dated May 10, 2010 for U.S. Appl. No. 12/433,510, 9 pgs.
Office Action (Non-Final) dated Oct. 28, 2010 for U.S. Appl. No. 12/433,510, 11pgs.
EMEA, “Committee for Proprietary Medicinal Products Opinion Following an Article 10 Referral CYKLO-f (Tranexamic acid)”, EMEA Jul. 27, 2000, pp. 1-9.
Product Information Cyklokapron® Pfizer Australia, most recent amendment Mar. 11, 2008, pp. 1-8.
Package Leaflet: Information for the user, Cyklonova 500mg film-coated tablet. Leaflet approved Dec. 12, 2005. pp. 1-3.
1996 Physician's Desk Reference, 50th Edition, on Tranexamic acid (Cyklokapron), pp. 1950-1951.
Pilbrandt, A., et al., “Pharmaceutical and Bioavailability of Tranexamic Acid”, Eur. J. Clin. Pharmacol. (1981)-20: 65-72.
International Search Report from PCT/US2004/023528, (2004).
International Search Report from PCT/US2005/20558, (2005).
International Search Report from PCT/US2005/20563, (2005).
Alexander, D. A. et al, “Randomized trial comparing hysterectomy with endometrial ablation for dysfunctional uterine bleeding: psychiatric and psycho
Facemire John W.
Greiwe Jeffrey S.
Heasley Ralph A.
Modest Jason D.
Moore Keith A.
Ferring B.V.
Fetterolf Brandon
Fish & Richardson P.C.
Stone Christopher R
LandOfFree
Tranexamic acid formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tranexamic acid formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tranexamic acid formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665065